Sugi Predict

Sugi Predict / Compounds / SCHEMBL21765638

SCHEMBL21765638

SCHEMBL21765638

COC(=O)C(C(=O)OC)C(=O)C1(n2cccc2-c2ccccc2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.39
▸ ACHE P22303 1/20 0.36
▸ OPRM1 P35372 1/20 0.36
▸ OPRK1 P41145 1/20 0.36
▸ OPRL1 P41146 1/20 0.36
▸ ATM Q13315 1/20 0.35
▸ EGLN1 Q9GZT9 3/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ CYP26A1 O43174 1/20 0.34
▸ HDAC1 Q13547 3/20 0.33
▸ HDAC6 Q9UBN7 3/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ SLC6A3 Q01959 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21765817 0.95 KMT2A (0.37) KMT2AACHEOPRM1OPRK1OPRL1
SCHEMBL21765826 0.95 KMT2A (0.37) KMT2AACHEOPRM1OPRK1OPRL1
SCHEMBL21765637 0.94 KMT2A (0.37) KMT2AACHEOPRM1OPRK1OPRL1
SCHEMBL21747356 0.92 EGLN1 (0.36) KMT2AACHEOPRM1OPRK1OPRL1
SCHEMBL21765764 0.85 EGLN1 (0.33) ATMEGLN1ALDH1A1LMNA
SCHEMBL21747383 0.85 EGLN1 (0.35) EGLN1ALDH1A1KDM4EPOLB
SCHEMBL21765532 0.84 FAAH (0.36) KMT2AACHEMEN1ALDH1A1KDM4E
SCHEMBL21765758 0.84 SLC6A4 (0.35) EGLN1KDM4ECYP2C9CYP2C19SLC6A3
SCHEMBL21765631 0.84 ACHE (0.36) ACHEEGLN1KDM4ESLC6A3
SCHEMBL21765773 0.83 ACHE (0.36) ACHEEGLN1KDM4ESLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11970495-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2024-04-30 — — US disclosed
US-11945817-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2024-04-02 — — US disclosed
US-20230257379-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2023-08-17 — — US disclosed
US-20230257379-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2023-08-17 — — US disclosed
US-20230242527-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2023-08-03 — — US disclosed
US-20230242527-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2023-08-03 — — US disclosed
US-11655249-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2023-05-23 — — US disclosed
US-11655249-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2023-05-23 — — US disclosed
EP-3613742-B1 INDOLIZINE DERIVATIVES AND APPLICATION THEREOF IN MEDICINE KIND PHARMACEUTICAL (CN) 2022-12-07 — — EP disclosed
US-20210253570-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2021-08-19 — — US disclosed
CN-113004271-A Indolizine derivative and application thereof in medicine 杭州安道药业有限公司 2021-06-22 — — CN disclosed
US-11021478-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2021-06-01 — — US disclosed
CN-108484598-B Indolizine derivative and application thereof in medicine 杭州安道药业有限公司 2021-03-02 — — CN disclosed
US-20200165242-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2020-05-28 — — US disclosed
EP-3613742-A1 INDOLIZINE DERIVATIVES AND APPLICATION THEREOF IN MEDICINE Kind Pharmaceutical (CN) 2020-02-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257379-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE INMT, IDO1, IDO2 KMT2A 2472/4885ACHE 992/4885OPRM1 253/4885
US-11021478-B2 Indolizine derivatives and their application in medicine INMT, IDO1, IDO2 KMT2A 2472/4885ACHE 992/4885OPRM1 253/4885
US-11970495-B2 Indolizine derivatives and their application in medicine INMT, IDO1, IDO2 KMT2A 2472/4885ACHE 992/4885OPRM1 253/4885
US-20230242527-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE INMT, IDO1, IDO2 KMT2A 2472/4885ACHE 992/4885OPRM1 253/4885
US-11945817-B2 Indolizine derivatives and their application in medicine INMT, IDO1, IDO2 KMT2A 2472/4885ACHE 992/4885OPRM1 253/4885
US-20210253570-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE INMT, IDO1, IDO2 KMT2A 2472/4885ACHE 992/4885OPRM1 253/4885
US-11655249-B2 Indolizine derivatives and their application in medicine INMT, IDO1, IDO2 KMT2A 2472/4885ACHE 992/4885OPRM1 253/4885
US-20200165242-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE INMT, IDO1, IDO2 KMT2A 2472/4885ACHE 992/4885OPRM1 253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.